Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 20/20 | 0.51 |
| ▸ | PIK3R1 | P27986 | 14/20 | 0.51 |
| ▸ | PIK3CG | P48736 | 13/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.51 |
| ▸ | PIK3CB | P42338 | 7/20 | 0.51 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.51 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL935884 | 0.89 | PIK3R1 (0.44) | PIK3CDPIK3R1PIK3CGPIK3CAPIK3CB | |
| SCHEMBL2599465 | 0.89 | PIK3CD (0.41) | PIK3CDPIK3R1PIK3CGPIK3CAPIK3CB | |
| SCHEMBL2599467 | 0.87 | PIK3CD (0.39) | PIK3CDPIK3R1PIK3CGPIK3CAPIK3CB | |
| SCHEMBL16671078 | 0.84 | PIK3CD (0.43) | PIK3CDPIK3R1PIK3CGPIK3CAPIK3CB | |
| SCHEMBL14993340 | 0.84 | PIK3CD (0.51) | PIK3CDPIK3R1PIK3CGPIK3CAPIK3CB | |
| SCHEMBL935387 | 0.83 | PIK3CD (0.43) | PIK3CDPIK3R1PIK3CGPIK3CAPIK3CB | |
| SCHEMBL5607774 | 0.81 | PIK3CD (0.49) | PIK3CDPIK3R1PIK3CGPIK3CAPIK3CB | |
| SCHEMBL936006 | 0.81 | PIK3CD (0.39) | PIK3CDPIK3R1PIK3CGPIK3CAPIK3CB | |
| SCHEMBL935803 | 0.80 | PIK3R1 (0.46) | PIK3CDPIK3R1PIK3CGPIK3CAPIK3CB | |
| SCHEMBL9924638 | 0.80 | PIK3R1 (0.45) | PIK3CDPIK3R1PIK3CGPIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4561704-A2 | USE OF GLYCOGEN METABOLISM INHIBITORS FOR THE TREATMENT OF CANCER | The University Of Vermont (US) | 2025-06-04 | — | — | EP | claimed |
| WO-2024026458-A2 | USE OF GLYCOGEN METABOLISM INHIBITORS FOR THE TREATMENT OF CANCER | THE UNIVERSITY OF VERMONT (US) | 2024-02-01 | — | — | WO | claimed |
| EP-4110344-A2 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | The University Of Vermont (US) | 2023-01-04 | — | — | EP | claimed |
| EP-3074016-A2 | THERAPIES FOR TREATING MYELOPROLIFERATIVE DISORDERS | Gilead Sciences, Inc. (US) | 2016-10-05 | — | — | EP | claimed |
| WO-2015160986-A2 | COMBINATION THERAPIES | INFINITY PHARMACEUTICALS, INC. (US) | 2015-10-22 | — | — | WO | claimed |
| WO-2015160975-A2 | COMBINATION THERAPIES | INFINITY PHARMACEUTICALS, INC. (US) | 2015-10-22 | — | — | WO | claimed |
| EP-2916868-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A PDE4 INHIBITOR AND A PI3 DELTA OR DUAL PI3 DELTA-GAMMA KINASE INHIBITOR | Rhizen Pharmaceuticals S.A. (CH) | 2015-09-16 | — | — | EP | claimed |
| WO-2015081127-A2 | THERAPIES FOR TREATING MYELOPROLIFERATIVE DISORDERS | GILEAD SCIENCES, INC. (US) | 2015-06-04 | — | — | WO | claimed |
| WO-2014072937-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING A PDE4 INHIBITOR AND A PI3 DELTA OR DUAL PI3 DELTA-GAMMA KINASE INHIBITOR | RHIZEN PHARMACEUTICALS SA (CH) | 2014-05-15 | — | — | WO | claimed |
| EP-4731199-A2 | COMPOSITIONS COMPRISING ANTINEOPLASTONS AND METHODS OF TREATING COLORECTAL CANCER | Burzynski, Stanislaw R. (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-4731792-A2 | COMPOSITIONS COMPRISING ANTINEOPLASTONS AND METHODS OF TREATING LUNG CANCER | Burzynski, Stanislaw R. (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-4727534-A1 | COMPOSITIONS COMPRISING ANTINEOPLASTONS AND METHODS OF TREATING BREAST CANCER | Burzynski, Stanislaw R. (US) | 2026-04-22 | — | — | EP | disclosed |
| WO-2024263972-A2 | COMPOSITIONS COMPRISING ANTINEOPLASTONS AND METHODS OF TREATING UNCOMMON CANCERS | BURZYNSKI STANISLAW R (US) | 2024-12-26 | — | — | WO | disclosed |
| WO-2024263643-A1 | COMPOSITIONS COMPRISING ANTINEOPLASTONS AND METHODS OF TREATING BREAST CANCER | BURZYNSKI STANISLAW R (US) | 2024-12-26 | — | — | WO | disclosed |
| EP-2663309-A1 | PROCESSES FOR PREPARING ISOQUINOLINONES AND SOLID FORMS OF ISOQUINOLINONES | Infinity Pharmaceuticals, Inc. (US) | 2013-11-20 | — | — | EP | disclosed |
| EP-2571357-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | Intellikine, Inc. (US) | 2013-03-27 | — | — | EP | disclosed |
| WO-2012097000-A1 | PROCESSES FOR PREPARING ISOQUINOLINONES AND SOLID FORMS OF ISOQUINOLINONES | REN PINGDA (US) | 2012-07-19 | — | — | WO | disclosed |
| EP-2456444-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | Intellikine, Inc. (US) | 2012-05-30 | — | — | EP | disclosed |
| WO-2011146882-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | INTELLIKINE, INC. (US) | 2011-11-24 | — | — | WO | disclosed |
| WO-2011008302-A1 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS | INTELLIKINE, INC. (US) | 2011-01-20 | — | — | WO | disclosed |